SUMMARY Seventeen patients with intractable sciatica due to prolapse of a lumbar disc, treated by intradiscal injection of chymopapain (chemonucleolysis) were studied. Analysis of serial 24 hour urine collections showed a significant increase in urinary glycosaminoglycan after chemonucleolysis. This was not detected in four patients undergoing routine discography. Enzymic analysis of urinary glycosaminoglycan after chemonucleolysis suggested that the increase in levels was largely due to an increase in the amounts of chondroitin sulphate present, probably resulting from proteoglycan breakdown in the intervertebral disc. Eight of the patients treated by chemonucleolysis underwent serial computed tomography (CT). One month after the injection the only change seen was a loss of definition of the disc prolapse, which could be interpreted as a loss of turgidity in the disc as a result of proteoglycan breakdown by chymopapain. By six months the CT of those patients whose symptoms had improved showed that the degree of disc prolapse was usually less marked and the disc margin more clearly defined, suggesting that by this stage anatomical remodelling had occurred.
Chemonucleolysis has been widely adopted as a treatment for intractable sciatica. Its efficacy has been established in double blind studies,' and chemonucleolysis is now being recommended as the last step in the conservative treatment of sciatica before surgery. 3 The mechanism by which pain relief is obtained is not clearly understood. A widely held theory is that the enzyme relieves sciatica by degrading the proteoglycan content of the intervertebral disc, causing loss of glycosaminoglycan and water, resulting in 'shrinkage' of the disc and a reduction of pressure on the nerve root. 4 Chymopapain is capable of degrading proteoglycan in vitro,5 and two studies in vivo have shown a rise in urinary excretion of proteoglycan breakdown products after chemonucleolysis.6 7 Anatomical changes, including narrowing of the disc space and reduction in size of disc protrusion on serial CT studies, have also been reported anecdotally in successfully treated patients.8
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It has been suggested that the success of chymopapain in clinical trials may be due to spontaneous remission of symptoms,9 the act of injection into the disc itself, psychogenic factors,"' or the action of a separate agent in the formulation of the commercially available enzyme." The last of these possibilities is not consistent with the results of a recent trial. 12 Alternative mechanisms that have been proposed are reduction of inflammation which occurs at the interface between disc prolapse and the nerve root '3 and the destruction of a chemical mediator of In order to clarify the mechanism by which chemonucleolysis relieves sciatica the relationship between clinical results, urinary excretion of proteoglycan breakdown products, and anatomical change shown by CT has been studied in patients undergoing chemonucleolysis. and 24 hour urine samples were obtained pre-and postinjection. Eight of these patients underwent serial CT.
All 17 patients, whose details are shown in Table  1 , complained of unremitting symptoms and signs typical of lumbar disc prolapse. They had undergone a period of conservative treatment, including traction, an epidural injection of local anaesthetic and corticosteroid, and a minimum of two weeks' strict bed rest, usually as inpatients. Duration of symptoms ranged from three to 16 The urine sample was thawed and 0-25 ml was mixed with [2] [3] [4] [5] ml of a 16 [tg/ml solution of DMB in 0-1 M sodium formate buffer (pH [3] [4] [5] . The absorbance at 535 nm was determined immediately after mixing, and the value was compared with a standard curve for 0-100 pLg/ml of whale chondroitin sulphate. The 5 ml by the addition of 0-05 M TRIS. HCl (pH 8-0).
Partial purification with cetylpyridinium chloride was chosen for the digestion studies as this allowed concentration of material from day 0 and discogram urine, for which the levels of glycosaminoglycans were too low for accurate analysis.
DIGESTION OF URINARY GLYCOSAMINOGLYCANS
Digestions of the partially purified, papain digested material (above) were performed on 0-5 ml of the sample for 10 min at 37°C. Incubation mixtures contained 0-05 units of chondroitin ABC lyase, 0-05 units of chondroitin AC lyase, or 0-1 units of keratanase, and approximately 10 ,ug of glycosaminoglycan. Digestion was monitored by loss of reaction with DMB, and digestions of known amounts of whale chondroitin sulphate or keratan sulphate were used to optimise digestion conditions.
COMPUTED TOMOGRAPHY (CT)
The CT studies were performed on a Siemens Somaton 2 third generation machine, for which a standard routine for lumbar spine studies has been developed. 18 This routine is similar to that used in other centres. 19 Cuts, 4 mm thick, were used and the gantry was tilted to approximate the angle of each disc space in turn. Each patient was studied on three occasions. A full CT study of the lumbar spine (L3 to SI) was performed immediately before chemonucleolysis and limited (one level) cuts of the treated disc space were obtained one month and approximately six months after the procedure.
The following measurements were performed. The anteroposterior (AP) extent of the disc protrusion was estimated on each occasion. A subjective assessment of the definition of the posterior peripheral margin of the disc material was also made. Table 2 . All patients were found to have a disc protrusion confined by the annulus at the level injected. One was described as having a 'very firm' disc protrusion. This was a patient who had had sciatica for two years, and it was assumed that the enzyme was unable to affect such a degenerate disc. In three patients the nerve root was found to be tethered to the underlying disc protrusion by adhesions, and this was thought to be contributing to the patients' lasting symptoms. One of these three was also found to have a previously unsuspected extruded disc fragment at the disc below the one injected. There was no obvious cause found at operation to explain the failure of the enzyme injection in two patients, and it is worth noting that one of these showed no increase in excretion of urinary glycosaminoglycan after the enzyme injection.
URINARY LEVELS OF MATERIAL REACTIVE WITH DMB AFTER CHEMONUCLEOLYSIS OR DISCOGRAM
The amount of glycosaminoglycan in the urine was measured by reaction with DMB. As seen in Fig. 1 the dose-response for the absorbance at 535 nm of whale chondroitin sulphate reacting with DMB was linear in water and urine, with no significant interference in urine. On average, the amount of reaction with DMB increased after chemonucleolysis, reaching a maximum two days after injection (Fig. 2) . The level then fell and approached preinjection values by day 5 postinjection. The levels Day after injection Injection Papain digestion of the precipitates cetylpyridinium chloride treatment re removal of about 40% of the reactivity material from preinjection urine, and material from postinjection urine. digested by papain was probably comp glycoproteins, which are coprecipitate aminoglycans from urine, and may r extent with DMB.23 24 The specificity of the glycosaminogl confirmed as the chondroitinases fai keratan sulphate under the conditioi keratanase failed to digest whale chc phate. 4 5 proportion of chondroitin sulphate in the DMB reactive material and the total level of this material in the urine (Fig. 2 ) increased after injection of chymopapain.
The level of digestion achieved with keratanase also increased after chemonucleolysis ( (Fig. 4) . The lack of definition of the disc observed in the CT studies at one month was not a prominent feature in the five patients who underwent CT at six months, only one being judged still to have poor definition of the disc protrusion. (Fig. 5a) shows a central disc protrusion (AP extent 7 mm, cross sectional thecal area 43 mm2) with an additional focal bulge just right of centre. At one month (Fig. 5b ) the posterior aspect of the protrusion was less well defined, but the AP extent of the protrusion and the thecal area remained virtuallr unchanged (AP extent 8 mm, thecal area 40 mm ). By six months (Fig. Sc) generalised without the focal lesion, and although the AP extent of the protrusion remained unchanged (7 mm), the cross sectional area increased to 52 mm2.
Discussion
The method we have adopted for the measurement of glycosaminoglycan in urine was developed for the measurement of glycosaminoglycan release from cartilage cultures,'6 and has recently been used successfully for the determination of glycosaminoglycan content of kidney basement membranes. 25 The products of digestion of chondroitin-4-sulphate with testicular hyaluronidase (mainly tetrasaccharides) are fully active in the reaction with DMB, whereas the disaccharide products of digestion with the glycosaminoglycan lyases give no colour reaction.26 This method will therefore quantify sulphated glycosaminoglycans of tetrasaccharide or larger. Although we have shown that other, proteinaceous, components of urine also give a positive reaction with DMB, the method can be successfully used in conjunction with specific polysaccharidases to provided an accurate measure of the quantity of specific glycosaminoglycans in urine.
The results of such analyses show an increase in urinary excretion of glycosaminoglycans in the majority of patients receiving chymopapain. This supports previous reports employing different methods of analysis, which also showed an increased excretion of glycosaminoglycans in the urine after chemonucleolysis.6 7 A lack of correlation between clinical success and urinary levels of material reactive with DMB is not surprising as the operative findings (Table 2) suggest that clinical failure is more dependent on factors such as tethering of the nerve root than failure of enzyme to break down the proteoglycan in the disc.
The finding that the control subjects undergoing discography showed no significant rise in the urinary material reactive with DMB indicates that increased levels of glycosaminoglycan after injection are not simply a response to injury caused by the injection. These results, on the contrary, strongly suggest that the increase in the urine of material reactive with DMB after chemonucleolysis is due to the degradation of the intervertebral disc proteoglycan by chymopapain.
The increases in the total amount of urinary material reactive with DMB after chemonucleolysis and in the proportion of this material which is chondroitin sulphate are consistent with the extra material being of cartilaginous origin. The appearance of some keratan sulphate in urine after chemonucleolysis is consistent with the breakdown of intervertebral disc proteoglycan, which contains substantial quantities of keratan sulphate compared with cartilage from other sources.27 8 The similarity in the proportion of the material sensitive to chondroitin ABC lyase and chondroitin AC lyase is evidence that very little dermatan sulphate was present in the urine. Human intervertebral disc contains negligible quantities of dermatan sulphate. 27 It is possible to determine the approximate amount of extra glycosaminoglycan excreted as a result of chymopapain injection at one level to be about 50 mg. This provides a minimal estimate of the amount of glycosaminoglycan mobilised by chemonucleolysis because the proportion of glycosaminoglycan excreted, as opposed to metabolised, is not known. Kaplan Saklatvala.3' The delay between injection of chymopapain and the detection of increased levels of urinary material reactive with DMB (often 48 hours or more) is probably related to the time needed for the diffusion of degraded proteoglycan from the avascular nucleus pulposus to the nearest capillary bed in the cartilaginous endplates. The delay is unlikely to be due to a build up of proteoglycan breakdown products in the blood as Bowness and Parkinson failed to find increased amounts of gl 1cosaminoglycan in serum after chemonucleolysis. Kaplan and Meyer reported the delay between intravenous injection of dermatan sulphate and the appearance in the urine to be minutes rather than days,29 although a recent study showed that the passage of glycosaminoglycans through the glomerulus was restricted. 24 Residual chymopapain may remain for a considerable time in the disc, so that proteoglycan degradation could be continuing, leading to later appearance of some glycosaminoglycan in the urine.32 33 The CT findings in this small series are revealing. In the first month after the injection there was virtually no change in the objective measurements of the disc protrusion in any of the patients, whether or not there was clinical improvement. The most consistent change at one month was the loss of definition between the thecal sac and the disc material. This change might be due to a loss of turgidity within the disc causing the annulus to become less rigid and thus less sharply defined, lending further support to the theory that chemonucleolysis reduces pressure on the nerve root by reducing the hydrostatic pressure within the prolapse, rather than removing the prolapse itself. That the prolapse still remains one month after the injection is perhaps not surprising in view of the observed lack of action of this enzyme on collagen.
Within six months of the injection the definition of the disc margin on CT had almost returned to normal in those patients whose clinical condition improved. More obvious anatomical changes, however, had also occurred, with reduction in the size of the disc prolapse and a reciprocal increase in the available cross sectional area in the majority of the patients. At this stage the turgidity of the disc may have returned, so that the sciatica is now relieved by the anatomical 'shrinkage' of the disc away from the nerve root. The delay of between one and six months might represent the time taken for the collagenous structure of the disc to reorganise after the loss of a large proportion of its proteoglycan content.
It is interesting that major changes in anatomy are not essential for the relief of sciatica and subtle changes in the outline of the disc prolapse, as illustrated in Fig. 5 , appear to be sufficient to result in the relief of pain.
The permanent relief of sciatica after chemonucleolysis may therefore be a two stage process. Within days of the injection there is release of proteoglycan from the disc, which results in loss of turgidity within the disc and the relief of pressure on the nerve root, perhaps explaining why patients often notice relief of their sciatica within a few days of the injection. After a number of months anatomical changes occur within the disc, causing a reduction in size of the disc prolapse, thus relieving the pressure on the nerve root on a more permanent basis. 
